Retinol Binding Protein 4 Protein in Alopecia Areata Treated With Barcitinib

Sponsor
South Valley University
Study ID
NCT06545110
Phase
PHASE1
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
12 Years - 60 Years
Healthy Volunteers
Not accepted

Interventions

  • Baricitinib Oral Tablet — DRUG
    Baricitinib 2/4mg giving to patients with sever alopecia areata after assessment Retinol Binding Protein 4 and its genetic variations.

Study Details

Assess serum and tissue retinol binding protein 4 in patients with severe alopecia areata in correlation with healthy individuals . Estimate genetic profile of retinol binding protein4 in severe alopecia areata patients Assess possible role of retinol binding protein 4 genetic mutation in response to barcitinib treatment in patients with severe alopecia areata .

Key Dates

Start date
Sep 1, 2023
Status verified
Aug 2024
Primary completion
Sep 30, 2024
Completion
Oct 30, 2024

Study Design

Enrollment
120 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: group A
    60 patient with sever alopecia areata
  • Placebo Comparator: group B
    60 healthy individuals

Primary Outcome Measure

Assess serum and tissue retinol binding protein 4 in patients with severe alopecia [ Time Frame: baseline ]

Related Studies